Fragile X syndrome and neurodevelopmental disorders
Connecta Therapeutics S.L. concentrates its clinical research on Fragile X syndrome, with studies centered on adult males affected by this neurodevelopmental disorder.
- Fragile X syndrome
- Neurodevelopmental disorders
- Adult male patient population
The sponsor’s current trial portfolio is focused on evaluating therapeutic options relevant to the clinical features associated with Fragile X syndrome.
Safety and tolerability research
Its clinical programme includes research into the safety and tolerability of investigational treatment approaches for people living with Fragile X syndrome.
- Safety assessment
- Tolerability evaluation
- Placebo-controlled comparison
This area reflects a strong therapeutic interest in understanding how candidate treatments are received in a rare neurological condition.
CNS-directed therapeutic development
The sponsor is involved in central nervous system-focused drug development, with attention to treatment strategies that may address the underlying manifestations of Fragile X syndrome.
- Central nervous system therapeutics
- Rare disease drug development
- Neuropsychiatric symptom domains
Its research activity is aligned with clinical interest in therapies for cognitive, behavioural, and neurological aspects of the disorder.
Early clinical development in a rare disease setting
Connecta Therapeutics S.L. also supports early clinical research in a rare disease context, examining investigational therapies in a tightly defined patient population.
- Early-stage clinical research
- Rare disease therapeutics
- Clinical evaluation in limited patient cohorts
The company’s activity is concentrated in Spain, with collaboration across a small number of research sites.
